News

The Arrangement Covers Process Transfer, Process Development and GMP Manufacture of Affibody's Candidate

We are so glad to be part of such an exciting project with the Swedish company INTERVACC, who we are working with on manufacturing of Strangvac® including the large-scale production of the vaccine against equine strangles.

3P and Xenikos started their collaboration in 2015 and now, according to this new agreement, 3P is responsible for the process transfer and scale-up, cGMP production for clinical trials and process validation.

3P Biopharmaceuticals has recently increased its analytical capacities and capabilities.

3P Biopharmaceuticals has successfully completed the project for the expansion and improvement of its facilities in Noáin (Spain) that had been carried out over the past months. The investment exceeded the 5 million euros invested in this project in addition to the 8 million euros that 3P has invested since 2013.

3P Biopharmaceuticals has been selected as one of the Main Success Stories in the Spanish biotech sector in the last 10 years.

Did you miss our webinar about our experience using ambr® 15 with CHO-S cell line for the production of monoclonal antibodies?

Cardiomesh is the project in which 3P Biopharmaceuticals and Viscofan are collaborating to develop and manufacture an innovative cell therapy product.

3P Biopharmaceuticals is incorporating a new Laboratory Information Management Systems (LIMS) from Abbott Informatics, a global leader provider of laboratory solutions. The implementation phase is currently in progress together with Abbott Informatics who are also ensuring the specific training required for the completion of each milestone.